

(A)

- **Aksungar F. B., Topkaya A.E., Yildiz Z. et al. (2008):** Coagulation status and biochemical and inflammatory markers in multiple sclerosis. *Journal of Clinical Neuroscience* ;15(4) : 393–397.
- **Alessandra F., Diego I., Pasquale C. et al.(2001):** Homocysteine and transmethylation uremia. *Kidney Int.*;59:230-33.
- **Alexandroff A.B, Pauriah M. , Camp R.D. et al.(2009):** More than skin deep: atherosclerosis as systemic manifestation of psoriasis. *Br J Dermatol.*;161:1–7.
- **Andrès E., Loukili N.H., Noel E. et al. (2004):**Vitamin B₁₂ (cobalamin) deficiency in elderly patients. *C.M.A.J.* ; 171 (3): 251-259.
- **Andrès E., Noel E. and Ben Abdelghani M. (2003):**Vitamin B₁₂ deficiency associated with chronic acid suppression therapy. *Ann Pharmacother* ;37:1730.
- **Armstrong A.W.,Voyles S.V., Armstrong E.J. et al.(2011):** Angiogenesis and oxidative stress.Common mechanisms linking psoriasis with atherosclerosis . *J Dermatol Sci.*;63(1):1-9.
- **Augey F.,Renaudier P. and Nicolas J.(2006):**Gneralized pustular psoriasis (Zumbusch): a french epidemiological survey. *Eur.J.Dermatol.*;16 (6):669-73.

(B)

- **Balion C. and Kapur B.M. (2011):**Folate :Clinical Utility of Serum and Red Blood Cell Analysis.Clinical laboratory news; 37 (1):8-10.
- **Balkrishnan R. (2006):**Clobetasol propionate for psoriasis: are ointments really more potent .J. of Drugs Dermatol;.5:527-532.
- **Bar-On H., Kidron M. and Rosenberg I.(2000):** Plasma total homocysteine levels in subjects with hyperinsulinemia. J Intern Med;247(2):287-94.
- **Batchelor J. M., Ingram J. R. and Williams H. (2009):**Adalimumab vs. Methotrexate for the Treatment of Chronic Plaque Psoriasis.J. of Arch Dermatol.;145: 704-706.
- **Berger T.G., Duvic M., Van Voorhees A.S. et al. (2006):**The use of topical calcineurin inhibitors in dermatology:safety concerns.Report of the american Academy of Dermatology Association Task Force.J Am Dermatol;54(5):818-823.
- **Blom H.J.(2000):**Consequences of homocysteine export and oxidation in vascular system.Seminars in thrombosis and Homeostasis;26 (3):227-36.
- **Boehncke W.H.(2012):**Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting.J Rheumatol.;39 (2):441-4.

- **Boehncke W.H. and Boehncke S.(2012):**Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.Curr Rheumatol Rep.;14(4):343-8.
- **Bonish, B.K. (2006):** Lessons learned from psoriatic plaques concerning mechanisms of tissue repair,remodeling, and inflammation. J of Investig Dermatol Symp.;1(1):16-29.
- **Bowcock A. (2005):**Psoriasis pathophysiology: current concepts of pathogenesis.J. Ann Rheum Dis.; 64(2): 30-36.
- **Bowcock A. and Krueger J.(2005):**Getting under the skin :the immunogenetics of psoriasis.Nat Rev Immunol;5:699-711.
- **Boyman O., Conrad C. and Tonel G. (2005):** Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor- α .J. Exp. Med.; 199: 731-736.
- **Bronstrup A., Hages M. , Prinz-Langenohl R .et al.(1998):** Effects of folic acid and combination of folic acid and vitamine B12 on plasma Hcy level in healthy young women.American Journal of clinical nutrition; 68:1104-10.
- **Burke G.I., Bertoni A.G. and Shea S.(2008):** The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease:the multi-ethnic study of atherosclerosis.Arch Intern Med;168:928-35.

(C)

- **Cacciari E., Salardi S. and Sassi S.(2000):** Homocysteine, serum folate, and vitamin B12 in very young patients with type I diabetes mellitus. *J Ped Endocrinol Metab*;13(9):1621-627.
- **Cakmak S.K., Gul U. , Kilic C. et al.(2009):** Homocysteine, vitamin B12 and folic acid levels in psoriasis patients .*J Eur Dermatol Venerol*;23(3):300-03 .
- **Cameron H. and Dawe R. (2009):** Narrowband UVB phototherapy. *J. of BMJ.* ;338: 2212-2213.
- **Camisa C. (2005):** Two considerations for patients with psoriasis and their clinicians. *J of Ann Rheum Dis.*;64 (2): 2.
- **Carmel R.(2000):** Current concepts in cobalamin deficiency. *Annu Rev Med* ; 51: 357-75.
- **Carmel R. (2003):** Mild transcobalamin I (haptocorin) deficiency and low serum cobalamin concentration. *Clin Chem* ;49:1367-1374.
- **Carmel R., Aurangzeb I. and Ojan D.(2001):** Associations of food-cobalamin malabsorption with ethnic origin, age, *Helicobacter pylori* infection, and serum markers of gastritis. *Am J Gastroenterol.*;96:63-70.
- **Casas J.P., Shah T., Hingorani A.D., et al.(2008):** C reactive protein and coronary heart disease: a critical review. *J Intern Med.*; 264:295-314.

- **Chen P., Wolf W.R., Castanheira I. et al.(2010):**A LC/UV/Vis method For determination of cyanocobalamin (V B12) in multivitamin dietary supplements with on-line sample clean-up.The royal society of chemistry Anal methods ; 2 :1171-1175.
- **Chodorowska G., Wojnowska D. and Juskiewicz-Borowiec M.(2004):** C-reactive protein and alpha -2 macroglobulin plasma activity in medium – severe and severe psoriasis.J Eur Acad Dermatol Venerol.;18:180-183.
- **Choi W.J., Park E.J. , Kwon I.H. et al.(2010):**Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Dermatol;22(3):300-306.
- **Cohen A.D., Bonne D.Y. , Reuveni H. et al. (2005):** Drug exposure and psoriasis vulgaris:Case control and case crossover studies. Acta Derm Venereol .;85:299-303.
- **Coimbra S., Oliveria H. , Reis F. et al.(2010):** C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy.J Eur Acad Dermatol Venereol. ;24:789–96.
- **Collins T. and Cybulsky M.I.(2001):**Kappa B:Pivotal mediator or innocent bystander in atherogenesis?J Clin Invest ;107:255-64.
- **Colucci, M., Cattaneo M. and Martinelli I. (2008):** Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J. Thromb. Haemost.; 6:1571-1577 .

- **Conrad J, Brosstad F. , Lie Larsen M.et al.(1983):** Molar antithrombin concentration in normal human plasma . Haemostasis ;13 (6): 363–368.
- **Coppola A., Davi G. and Stefano V.(2000):**Homocysteine ,coagulation ,platelet function and thrombosis.Seminars in thrombosis and homeostasis;26(3):243-54.
- **Croce K. and Libby P. (2007):** Intertwining of thrombosis and inflammation in atherosclerosis. Curr Open Hematol.;14:55-61.
- **Croft D.N., Lim C.C. and Taylor J.F.N.(1968):** Deoxyribonucleic acid (DNA) loss, cell loss and cell turnover in exfoliative psoriasis.Br J Derm.;80:153.
- **Crowther M.A. and Kelton J.G. (2003):**Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed lassification system.Ann.Intern.Med.138(2):128-34.

(D)

- **Daneshpazhooh A., Homayoon M. , Maryam A. et al. (2004):**Tongue lesions in psoriasis: a controlled study .J. of BMC Dermatology.;1471 (5945):4-16.
- **Danilenko D.M. and Zheng Y. (2007):** Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature International weekly. J.of Science; 445:648–651.

- **Darouti M. and Abdel Hay R.(2010):** psoriasis highlights on pathogenesis ,adjuvant therapy and treatment of resistant and problematic cases.J Egypt Women Dermatol;7:64-70.
- **DuClos T.(2000):** Function of C-reactive protein. Ann Med.;32:274-278.
- **Dummer R., Goldinger S.M. and Schmid P. (2006):** Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. J. of Dermatology; 213: 134–139.
- **Duvic M., Krueger G.G., Feldman S.R. et al. (2005):** Two considerations for patients with psoriasis and their clinicians J. of .Ann Rheum Dis.;64(1 2):30-6.

(E)

- **Eferl R. (2005):**Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins.Nature J. of science. ;437 (7057): 369–75.
- **Ehl S., Gering B., Bartmann P.et al.(1997):**C-reactive protein is a useful marker for guiding duration of antibiotictherapy in suspected neonatal bacterial infection. Pediatrics; 99:216-221.
- **Eldibany M.M .and Caprini J.A.(2007):** Hyperhomocystenimia and thrombosis:an overview. Arch Pathol Lab Med. ;131:872-884.

- **Elmets C.A., Menter A. and Korman N.J. (2010):**Guidelines of care for the management and treatment of psoriasis with topical therapies. J. of Am Acad Dermatol. ; 62(1):114-35.

(F)

- **Fairhurst D.A., Ashcroft D.M. and Griffiths C.E. (2005):**Optimal management of severe plaque form of psoriasis . J. of Am Clin Dermatol.; 6(5):283-94.
- **Federman D.G., Shelling M. , Prodanovich S. et al. (2009):**Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol. ;160:1–7.
- **Feldman S.R. (2009):**Psoriasis. Practical Ways to Improve Patients' Treatment Outcomes.J. of Winston-Salem, NC: Medical Quality Enhancement Corp. ;1477 (7525): 4-35.
- **Feldman S. R. and Krueger G. G. (2005):** Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis.; 64: 65-68.
- **Feldman S.R., Margolis D.J. ,Rolstad T. et al.(2005):** Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.J Am Acad Dermatol; 52:434 - 444.
- **Fluhr J.W. (2008):** Emollients, moisturizers, and keratolytic agents in psoriasis.J. of Clinics in Dermatology; 26:380.

- **Fortune D.G., Main C.J. and O'Sullivan T.M. (2005):**Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress.J. of Ann Rheum Dis.; 64 (2) : 18–23.

(G)

- **Gabay C. and Kushner I. (1999):**Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation.N Engl J Med. ;340:448-454.
- **Galletti P., Ingrosso D. , Manna C. et al.(1995) :** Protein damage and methylation mediated repair in the erythrocyte. Biochem J.;306:313-25.
- **Gaspari A.(2006):**Innate and adaptive immunity and the pathophysiology of psoriasis.J Am Acad Dermatol;54(3):67-80.
- **Gattu S. and Rashid (2009):**308-nm excimer laser in psoriasis vulgaris, scalp psoriasis and palmoplantar psoriasis. J. of the European Academy of Dermatology & Venereology; 23(6):36-41.
- **Gelfand J.M., Dommasch E.D. , Shin D.B. et al. (2009):**The risk of stroke in patients with psoriasis.J Invest Dermatol .;129:2411-2418.
- **Gelfand J.M., Neimann A.L., Shin D.B. et al. (2006):** Risk of myocardial infarction in patients with psoriasis. JAMA.; 296:1735-1741.
- **Gelfand J.M., Shin D.B., Neimann A.L.et al.(2006):**The risk of lymphoma in patients with psoriasis.J Invest Dermatol.; 126 (10) :2194-2201.

- **Gelman A. E., Kreisel D. ,Krupnick A. S. et al. (2002) :** Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. *Nature J. of Medicine*; 8: 233–239.
- **Ghazizadeh R., Shimizu H. , Tosa M. et al.(2010):** Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease. *Int J Med Sci. ; 7(5): 284–289.*
- **Gisoni P. and Girolomoni G. (2009):**Psoriasis and atherothrombotic disease:Disease specific and non disease specific risk factors.*Semin Thromb Hemost . ; 35:313-324.*
- **Gisoni P., Tessari G . and Conti A. (2007):** Prevalence of metabolic syndrome in patients with psoriasis: a hospital based case control study. *Br J Dermatol . ;157:68-73.*
- **Gladman D.D., Antoni C. , Mease P.et al.(2005):** Psoriatic arthritis:pidemiology, clinical features, course, and outcome. *Ann Rheum Dis. ;64 (2):14-7.*
- **Grrifiths C.E.. and Barker J.W. (2007):** Pathogenesis and clinical features of psoriasis .*Lancet;370:263-71.*
- **Grrifiths C.E.,Christophers E., Barker J.W. et al. (2007):**A classification of psoriasis vulgaris according to phenotype .*Br J. Dermatol; 156:258-262.*

- **Gudjonsson J.E. and Elder J.T. (2007):** Psoriasis: epidemiology. *J. of Clinics in Dermatology* ; 25 (6):535–46.
- **Guilliams T.G.(2004):** Homocysteine a risk factor for vascular disease: Guidelines for the clinical practice. *The Journal of the American Nutraceutical Association* ;7(1): 11-24.
- **Guo H,Chi J., Xing Y. and Wang p. (2009):**Influence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina. *Indian J Med Res.*; 129:279-284.
- **Gupta A.K., Madzia S.E. and Batra R. (2004):**Etiology and management of seborrheic dermatitis. *J. of Dermatology*; 208:89-93.
- **Guttorsmen A.B., Scheneede J. , Fiskerstrand T. et al.(1994):** Plasma concentration of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. *J Nutr.*;124:1934-941.

(H)

- **Hagforsen E., Awder M. , Lefvert A.K. et al.(2002):**Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?*Acta Derm Venereol.* ;82 (5) : 341-6.
- **Hamminga E.,Van Der Lely A. , Neumann H. et al.(2006):**Chronic inflammation in psoriasis and obesity:implications for therapy.*Med hypothesis* ;67(4):768-73.

- **Handy D.E., Zhang Y. and Loscalzo J.(2005):**Homocysteine downregulates glutathione peroxidase (GPx1) by decreasing translation.J. Biol. Chem.; 280:15518-15525.
- **Hankey G.J., John W. , Eikelboom J.W. et al.(2004):**Clinical usefulness of plasma homocysteine in vascular disease. MJA; 181 (6): 314-318 .
- **Hansson G.K.(2005):**Inflammation, atherosclerosis and coronary artery disease.N Engl J Med.;352:1685-95.
- **Haslam D.W. and James W.P.(2005):**Obesity.Lancet ;366 (9492):1197-209.
- **Haynes W.G.(2002):** Hyperhomocysteinemia,vascular function and atherosclerosis :effect of vitamins:Cardiovascular drugs and therapy.Metabolism;16:391-99.
- **Helliwell P., Taylor W. , Gladman D. (2006):** Classification criteria for psoriatic arthritis . J. of Arthritis Rheum. ; 54: 2665-2673.
- **Henry J.(2001):**Clinical diagnosis and management by laboratory methods.20 th.edition.W.B.SaundersCompany,Philadelphia,PP.1435.
- **Herron M.D., Hinckley M. and Hoffman M.S. (2005):** Impact of obesity and smoking on psoriasis presentation and management .J. of Arch Dermatol.;141:1527-1534.
- **Higgins M.(2000):**Alchol,smoking and psoriasis.Clin Exp Dermatol.;1:195-65.

- **Hoffbrand A.V. and Weil D.G. (2001):** The history of folic acid.Br J Haematol .;113 (3): 579–589.
- **Homey B.(2005):**Chemokines and inflammatory skin diseases. Adv Dermatol.;21:251-77.

(K)

- **Kaplan M.J.(2008):** Cardiometabolic risks in psoriasis: differential effects of biologic agents.Vascular health and risk management ;6 :1229-1235.
- **Kaptan K., Beyan C. , Ural A.U. et al.(2000):** Helicobacter pylori — Is it a novel causative agent in Vitamin B12 deficiency?Arch Intern Med;160:1349-53.
- **Karabudak O., Ulusoy R.E. , Erikci A.A. et al.(2008):** Inflammation and Hypercoagulable State in Adult Psoriatic Men. Acta Derm Venereol .; 88: 337–340.
- **Kaspersick-Zajac A., Brzoza Z. and Rogala B.(2008):**Platelets function in cutaneous diseases.Platelets;19:317-321.
- **Kaye J.A., Li L. and Jick S.S. (2008):** Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J dermatol.;159:895-902.
- **Kazemi B., Eshraghiar K. , Omrani G.R.et al. (2006):**Homocysteine level and coronary artery disease.Angiology ; 57:9-14.

- **Khajuria A. and Houston D.S.(2000):** Induction of monocyte tissue factor expression by homocysteine :a possible mechanism for thrombosis.Blood ; 96(3):966-72.
- **Khor B. and Van Cott E.M.(2010):** Laboratory tests for antithrombin deficiency.Am J Hematol.; 85(12):947.
- **Kim G.K.(2010):**The Rationale Behind Topical Vitamin D Analogs in the Treatment of Psoriasis. Where Does Topical Calcitriol Fit In? J Clin Aesthet Dermatol. ; 3(8): 46–53.
- **Kimbal A.B., Gordon K.B., Langley R.G.et al. (2008):** Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trials J. of Arch Dermatology; 144:200-207.
- **Korte W., Clarke S. and Lefkowitz J.B.(2000):** Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol.; 113(1): 123-127.
- **Krueger J.G. (2005):**Psoriasis pathophysiology: current concepts of pathogenesis.J. of Ann Rheum Dis. ; 64(2):30-36.
- **Krueger J.G. and Ellis C.N. (2005):** Psoriasis-recent advances in understanding its pathogenesis and treatment.J. of Am. Acad. Dermatol.;53 (1): 94–100.
- **Kuhle S., Lane D.A. , Jochmanns K. et al. (2001):**Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism.Thromb Haemost.;86(4):1007-11.

- **Kural B.V., Orem A. ,Cimsit G.et al. (2003):**Plasma homocysteine and its relationship with atherothrombotic markers in psoriatic patients.Clinical Chimica Acta.; 332 : 23-30.

(L)

- **Lawrence de Koning A.B. , Werstuck G.H. , Zhou J. et al.(2003):**Hyperhomocysteinemia and its role in the development of atherosclerosis.Clinical Biochemistry;36:431-441.
- **Leary F.O. and Samman S.(2010):** Vitamine B12in health and disease.Nutrients ;2:299-316.
- **Lebwohl M.(2003):** Psoriasis.Lancet ;361:1197-1204.
- **Lee R.E.,Gaspari A.A., Lotze M.T.et al.(1988):** Interleukin 2 and psoriasis.Arch Dermatol;111:645-9.
- **Lentz S.R .(2001):**Does homocysteine promote atherosclerosis [editorial]?Arterioscler Thromb Vasc Biol. ;21(9):1385-1386.
- **Lesueur F., Lefevre C., Has C. et al.(2007):** Confirmation of psoriasis susceptibility loci on chromosome 6p21 and 20p13 in French familiesJ Invest Dermatol.; 127:1403–9.
- **Libby P.(2008):**Role of inflammation in atheroscelorisis associated with rheumatoid arthritis. Am J Med;121(1):21-31.

- **Lloyd-Jones D.M., Liu K., Tian L. et al.(2006):**Narrative reviewe assessment of C-reactive protein in risk prediction for cardiovascular disease. *Ann Intern Med.*; 145 (1): 35–42.
- **Liu Y., Helms C. and Liao (2008):**A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.*J. of Clinical Immunology.* ; 4 (5): 565-571.
- **Loscalzo J. (2006):** Homocysteine trials—clear outcomes for complex reasons.*N Engl J Med.*;354(15):1629-1632.
- **Loscalzo J.(2009) :** Homocysteine mediated thrombosis and angiostasis in vascular pathobiology.*J Clin Invest.*;119(11):2303-3205.
- **Louden B.A., Pearce D.J., Lang W.et al. (2004):** A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. *Dermatol Online J.*; 10 (2) : 7.
- **Lowes M.A., Chamian F., Abello M.V. et al. (2005):** Increase in TNF- α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).*Proc Natl Acad Sci USA.* ;102:19057–62.

(M)

- **Maclean P.S. and Tait R.C. (2007):** Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. *Drugs*; 67 (10): 1429–1440.

- **Malebra M., Gisoni P. , Radaeli A. et al.(2006):** Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. *Br J Dermatol.*;155:1165-1169.
- **Mallbris L., Akre O. , Granath F. et al. (2004):** Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. *Eur J Epidemiol*;19:225-230.
- **Mandell B.F.(2012):** Fire, skin, and fat: Inflammation, psoriasis, and cardiovascular disease. *Cleveland Clinic Journal of Medicine* ; 79(6): 376.
- **Markle H.V. (1996):** Cobalamin. *Crit Rev Clin Lab Sci* ;33:247-356.
- **Marks J. and Shuster S.(1970):** Small intestinal mucosal abnormalities in various skin diseases .Fact or fancy? *Gut*;11(4):281-291.
- **Marongiu F., Sorano G.G. , Bibbo C. et al.(1994):** Abnormalities of blood coagulation and fibrinolysis in psoriasis. *Dermatology* ; 189: 32–37.
- **Mayer U., Fillipovsky J. and Dolejsova M.(2006):** Mild hyperhomocysteinemia is associated with increased aortic stiffness in general population . *J Hum Hypertens.*;20:267-71.
- **McDonald CJ and Calabresi P.(1978):** Psoriasis and occlusive vascular disease. *Br J Dermatol*;99:469-475.
- **McFadden J.P. and Baker B.S. (2009):** Psoriasis and streptococci: the natural selection of psoriasis revisited . *J. of Dermatol.*;160 (5):929-937.

- **Mehlis S.L. (2003):** The immunology of psoriasis and biological immunotherapy. *J Am Acad Dermatol.*;49: (1): 44-50.
- **Menter A. and Farelly E . (2011):** Psoriasis comorbidities and association. *J Ital Dermatol Venerol*;146(1):9-15.
- **Menter A., Feldman S.R. , Weinstein G.D. et al.(2007):** A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol.*;56:1–15.
- **Milani R.V. and Lavie C.J.(2008):**Homocysteine :The rubick's cube of cardiovascular risk factor. *Mayo Clin Proc* ;83 (11) :1200-2.
- **Moens A.L., Vrints C.J. , Clayes M.J. et al.(2008):** Mechanisms and potential targets for folic acid in cardiovascular disease. *Am .J. Physiol. Heart Circ .Physiol.*;294:1971-1977.
- **Mohan I.V.,Jagroop I.A., Mikhailidis D.P.et al.(2008):** Homocysteine activates platelets in vitro. *Clin Appl Thromb Hemost.*;14(1):8-18.
- **Montecucco F. and Mach F.(2008):** New evidence for C reactive protein deposits in the arterial intima as a cardiovascular risk factor. *Cljn Interv Aging* ;3:341-349.
- **Mrowietz U., Elder J.T. and Barker J.(2006):** The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. *Arch Dermatol Res.*; 298:309-19.

- **Muhammad R., Fernhoff P., Rasmussen G. et al. (2001):**Neurologic impairment in children associated with maternal dietary deficiency of cobalamin. JAMA .;289(8):979-980.
- **Murase J.E., Chan K.K. , Garite T.J. et al. (2005):** Hormonal effect on psoriasis in pregnancy and post partum.J .of Arch Dermatol.;141 (5): 601-606.

(N)

- **Naidich M.J. and Ho S.U. (2005):** Case 87: Subacute combined degeneration. Radiology; 237 (1): 101–5.
- **Nakano E.,Higgins J.A. and Powers H.G.(2001):** Folate protects against oxidative modification of human LDL.Br J Nutr.;86:637-639.
- **Naldi L. and Rzany B. (2006):** Psoriasis (chronic plaque).J.of online version of Clinical Evidence ; 15:1–39.
- **Nickoloff B.J. (2006):** Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J.of Investig Dermatol Symp Proc. ; 11(1):16-29.
- **Nickoloff B.J., Xin H. , Nestle F.O. et al. (2007):**The cytokine and chemokine network in psoriasis. Clin Dermatol. ;25:568–73.
- **Nicolas J.P. and Guéant J.L. (1994):** Absorption, distribution and excretion of vitamin B₁₂. Ann Gastroenterol Hepatol (Paris); 30(6):270-6,discussion;281-2.

- **Nijesten T. and Wakkee M.(2009):**Complexity of association between psoriasis and comorbidity .Inv J Dermatology;129:1601-1603.

(O)

- **Ohtsuka T.(2008):** The correlation between response to oral cyclosporine therapy and systemic inflammation:metabolic abnormality in patients with psoriasis .Arch Dermatol Res.;300:545-550.
- **Olson S.T. and Bjork I. (1994):** Regulation of thrombin activity by antithrombin and heparin. Sem. Thromb. Hemost. ; 20 (4): 373–409.
- **Opmeer B. C., Heydendael V. M., De Borgie C. A. et al. (2004):**Costs of Treatment in Patients with Moderate to Severe Plaque Psoriasis : Economic Analysis in a Randomized Controlled Comparison of Methotrexate and Cyclosporine.Arch Dermatol.J. of Dermatological Treatment ;140: 685-690.
- **Ortonne J.P., Lebwoh, M. and Griffiths C. (2003):**Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.J.of Dermatol; 13 (2):117-23.

(P)

- **Pang M.L., Murase J.E. and Koo J. (2008):**An updated review of acitretin--a systemic retinoid for the treatment of psoriasis. *Expert Opin Drug Metab Toxicol.*; 4 (7): 953-64.
- **Papp K., Saurat J.H. , Stingl G. et al. (2008):**Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis . *Br .J. Dermatol.* ;158(3):558-66.
- **Parrish J.A. and Jaenicke K.F. (2009):** Retinoids and Phototherapy for Psoriasis. *J.of Rheumatology .*; 36 (9): 1853 – 2136.
- **Passeron, T. and Ortonne, J. (2006):**Use of the 308-nm excimer laser for psoriasis and vitiligo.*J. of Clinics in Dermatology*; 24 (1):33-42.
- **Patel R.V., Shelling M.L., Prodanovich S.et al.(2011):** Psoriasis and vascular disease-Risk factors and outcomes. *J Gen Intern Med*;26(9):1036-49.
- **Persson E. Bak H. and Olsen O.H. (2001):**Substitution of valine for leucine 305 in factor VII a increases the intrinsic enzymatic activity.*J. Biol. Chem.*; 276 (31): 29195–29199.
- **Prodanovich S., Kirsner RS. , Kravetz J.D. et al. (2009):** Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality.*Arch Dermatol*; 145 (6):700–703.

- **Proença N.G.(2006):**Acropustulosis repens.Int J Dermatol.;45(4):389-93.
- **Prontera C., Martelli N. , Evangelista V.et al. (2007):**Homocysteine modulates the CD40/CD40L system. J Am Coll Cardiol.;49 (22): 2182-2190.

(R)

- **Radakovic A., Sonja L. , Seeber M.et al. (2009):**Failure of short-term psoralen and ultraviolet A light maintenance treatment to prevent early relapse in patients with chronic recurring plaque-type psoriasis .J.of Photodermatology Photoimmunology & Photomedicine.; 25(2):90-93.
- **Rahman P. and Elder J.T. (2005):** Genetic epidemiology of psoriasis and psoriatic arthritis .J.of Ann. Rheum. Dis.; 64 (2): 37–9.
- **Rampersaud G.C., Gail P.A. , Kauwell G.A. et al.(2003):**Folate :A key to optimizing Health and Reducing Disease Risk in the Elderly.J Am Coll Nutr. ; 22 (1): 1-8.
- **Raychaudhuri S.P.(2012):**Comorbidities of psoriatic arthritis - metabolic syndrome and prevention: a report from the GRAPPA 2010 annual. J Rheumatol.;39(2):437-40.
- **Refsum H .and Smith A.D.(2003):**Low vitamin B-12 stetus in confirmed alzehiemer 's disease as revealed by serum holotranscobalamin. J Neurol Neurosurg Psychatry;74:959-61.

- **Refsum H., Guttormsen A.B., Fiskerstrand T. et al. (1998):** Hyperhomocysteinemia in terms of steady state kinetics. *Eur J Pediatr.*;157(2):45-49.
- **Richard H.L., Fortune D.G., Chong S.L. et al. (2004):** Divergent beliefs about psoriasis are associated with increased psychological distress. *J. of Invest Dermatol.*; 123:49–56.
- **Ridker P.M. (2010):** Psoriasis, inflammation, and vascular risk: a problem more than skin deep? *European Heart Journal* ; 31: 902-904.
- **Rocha-Pereira P., Santos-Silva A., Rebelo I. et al. (2004):** The inflammatory response in mild and in severe psoriasis . *Br J Dermatol* .;150:917-928.
- **Rosamond W., Flegal K., Furie K., et al. (2008):** Heart disease and stroke statistics—2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* ;117:25–146 .
- **Rosenberg R.D., Bauer K.A. and Marcum J.A. (1986):** Antithrombin III "The heparin- antithrombin system". *Rev Hemtol* ; 2:351-416.
- **Rottman J.B., Smith T.L. and Ganley K.G. (2001):** Potential role of the chemokine receptors CXCR3, CCR4, and the integrin $\alpha E \beta 7$ in the pathogenesis of psoriasis vulgaris. *Lab. Invest.*; 81: 335-347.
- **Russel R.M. (1992):** Vitamin requirements in old age. *Age Nutrition* ;3:20-3.

- **Ryan C. and Menter A.(2012):**Psoriasis and cardiovascular disorders.G Ital Dermatol Venereol. ;147(2):179-87.

(S)

- **Sabat R ., Sterry W., Philipp S. et al. (2007):** Three decades of psoriasis research: where has it led us?Clinics in Dermatology.;25:504–9.
- **Sagoo, G.S., Tazi-Ahnini R., Barker J.W. et al. (2004):**Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28–q31 in Caucasian and Chinese Hans population. J of Invest Dermatol.; 122:1401–1405.
- **Salaradi S.,Cacciari E. and Sassi S.(2000):**Homocysteine, serum folate and vitamin B12 in very young patients with type 1 diabetes mellitusJ. Ped. Endocrinol. Metab.;13(9):1621-627.
- **Sauls, D.L, Lockhart E., Warren M.E., et al.(2006):**Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.Biochemistry; 45:2480-2487.
- **Saurat J.H. and Stingl G. (2008):** Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis .Br. J.of Dermatol .,158:558-566.

- **Scarpa R., Manguse F.D. and Arienzo A.(2000):** Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. *J Rheumatol*;27:1241-246.
- **Schaefer R.M., Teschner M. and Kosch M.(2002):** Folate metabolism in renal failure. *Nephrol Dial Transplant*; 17(5): 24-27.
- **Schmitt J. and Wozel G. (2005):**The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. *Dermatology*;210 (3):194-199.
- **Schneede J., Refsum H. and Ueland P.(2000):** Biological and environmental determinants of plasma homocysteine. *Seminars in thrombosis and homeostasis*;26(3):263-79.
- **Schon M.P. and Boehncke W.H.(2005):** Psoriasis. *N Engl J Med.* ; 352:1899–912.
- **Serdaroglu S., Parlak A.H., Engin B. et al.(2012):** The prevalence of psoriasis and vitiligo in a rural area in Turkey. *J Turk Acad Dermatol.* ;6(1):1261-2.
- **Sergeant A., Makrygeorgou A., Chan W.C. et al. (2008):** C-reactive protein in psoriasis. *Br J Dermatol.*;158:417-419.
- **Shelling M.L., Federman D.G., Prodanovich S. et al. (2008) :**Psoriasis and vascular disease: an unsolved mystery. *Am J Med.* ;121:360–5.

- **Shin D. B., Neimann A. L., Wang X. et al. (2006):**The risk of lymphoma in patients with psoriasis.J.of Investigative Dermatology; 126:2194–2201.
- **Sigurdsson V. (2008):** Home UVB phototherapy for psoriasis: Discrepancy between literature, guidelines, general opinions and actual use. Results of a literature review, a web search, and a questionnaire among dermatologists. Br. J. Dermatol; 154: 701-711.
- **Sivanesan S.P., Gattu S., Hong J. et al. (2009):** Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J. of the American Academy of Dermatology.; 61 (5): 793-8.
- **Smith C.H. and Barker J.N. (2006):** Psoriasis and its management. Br. J. of Medicine.; 333 (7564): 380–384.
- **Stamler J., Vaccaro O., Neaton J.D. et al., (1993):** Diabetes other risk factors and a 12 years cardiovascular mortality for men screened in the multiple risk factors intervention trial. Diabetes Care; 16:434-44.
- **Staples J. and Klein D. (2012):** Can nicotine use alleviate symptoms of psoriasis . Can Fam Physician. ; 58(4): 404–408.
- **Stover P.J. (2004):** Physiology of folate and vitamin B12 in health and disease. Nutrition Reviews; 62 (6) :3-12.
- **Strain J.J., Dowey L., Ward M. et al. (2004):** B vitamins, homocysteine metabolism and CVD. Proceedings of the nutrition society; 63:597-603.

- **Stroes E.S.G .,Van Fasseen E.E. , Yo M. et al.(2000):** Folic acid reverts dysfunction of endothelial nitric oxide synthase. *Circ Res* ;86: 1129-1134.

(T)

- **Tasi W.C., Li Y.H., Tasi L.M. et al.(2000):**Correlation of homocysteine levels with the extent of coronary atherosclerosis in patients with low cardiovascular risk profiles. *Am J Cardiol* ;85:49-52.
- **Taylor W. and Helliwell P. (2006):**Classification criteria for psoriatic arthritis: development of new criteria from a large international study.*J.of Arthritis Rheum.*; 54:2665-2673.
- **Teran C., Teran-Escalera C.N., and Balderrama C. (2010):**severe case of erythrodermic psoriasis associated with advanced nail and joint manifestations: a case report .*Med Case Reports.*; 4: 179.
- **Terwecoren A., Steen E., Benoit D. et al. (2009):**Ischemic stroke and hyperhomocysteinemia: truth or myth?*Acta neurologica Belgica* ;109 (3): 181–8.
- **Thambyrajah J. and Townend J.N.(2000):**Homocysteine and atherothrombosis – mechanisms for injury.*European Heart Journal* ; 21:967-974.
- **Tobin AM.,Hughes R.,Hand EB.et al.(2011):**Homocystein status and cardiovascularrisk factors in patients with psoriasis:a case control study .*Clin Exp Dermatol*;36(1):19-23.

- **Topal G., Brunet A., Millanvoye E. et al.(2004):**Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. *Free Radic. Biol. Med.*; 36:1532-1541.
- **Traub M. and Mshall K.(2007):**Psoriasis pathophysiologyConventional, and AlternativeApproaches to treatment. *Altern Med Rev.*;12(4): 319-330.

(U)

- **Ueland P.M.(1982):**Pharmacological and biological aspects of S-adenosylhomocysteine and Sadenosylhomocysteine hydrolase. *pharmacol Rev*;34:223-53.
- **Ueland P.M., Refsum H. , Stabler S. et al. (1993):**Total homocysteine in plasma or serum, methods & application. *Chin Chem*;39:1764-774.
- **Ungvari Z., Csiszar A., Edwards J.G. et al.(2003):** Increased superoxide production in coronary arteries of hyperhomocysteinemia: role of tumor necrosis factor-alpha, NADPH oxidase, and inducible nitric oxide synthase. *Arterioscler. Thromb. Vasc. Biol.* ;23:418-424.

(V)

- **Valeire L.N. (2009):** Prothrombin time and partial thromboplastin time consideration assay. *Clin Lab Med* ;29:253-263.
- **Van- Asselt D.Z., Blom H.J , Zuiderent R. et al. (2000):** Clinical significance of low cobalamin levels in older hospital patients. *Neth J Med* ;57:41-9.

- **Van- Boven H.H. and Lane D.A. (1997):** Antithrombin and its inherited deficiency states.Semin. Hematol. ;34 (3): 188–204.
- **Varga E.A., Sturm A.C., Misita C.P. et al.(2005):** Homocysteine and MTHFR mutation ; Relation to thrombosis and coronary artery disease. Circulation;111:289-293
- **Vena, G.A. and Cassano N. (2006):** Emerging drugs for psoriasis.J.of Expert Opin Emerg Drugs.; 11(4):567-96.
- **Vena G.A., Gianfranco Altomare G. Fabio Ayala F. et al.(2010)a:**Incidence of psoriasis and association with comorbidities in Italy: A 5-year observational study from a national primary care database.European Journal of Dermatology; 20 (5): 593-8.
- **Vena G. A.,Vestita M. and Cassano N. (2010) b:** Psoriasis and cardiovascular disease. Dermatologic therapy;23:144-151.
- **Victor F.C. and Gottlieb A.B. (2002):** TNF-alpha and apoptosis: Implications for the pathogenesis and treatment of psoriasis.J Drugs Dermatol;1:264-75.
- **Vitvitsky V. Dayal S., Stabler S. et al.(2004):**Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia.Am. J. Physiol. Regul. Integr. Comp. Physiol.; 287:39-46.

- **Voutilainen S., Rissanen T.H. ,Virtanen J.et al. (2001):**Low Dietary Folate Intake Is Associated With an Excess Incidence of Acute CoronaryEvents : The Kuopio Ischemic Heart Disease Risk Factor Study. *Circulation*;103:2674-2680.

(W)

- **Wakkee M., Thio H.B., Prens E.P.et al.(2007):**Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients.*Atherosclerosis* ;190:1-9.
- **Warino L. and Feldman S.R.(2006):**Clobetasol propionate for psoriasis: are ointments really more potent*J.of Drugs Dermatol* ;5:527-532.
- **Weatherhead S., Robson S.C. and Reynolds N.J. (2007):** Management of psoriasis in pregnancy.*Br.J. of Medicine*; 334:1218-1220.
- **Weinstein R.,Gelfand A.M. and Porter S.B.(2005):**Prevance and treatment of psoriasis in the united kingdom:a population based study.*J of Arch Dermatol* ;141:1537-1541.
- **Weleh G.N.,Upehurch G.R. and Farivar R.S.(1998):** Homocysteine induced nitric oxide production in vascular smooth muscle cells by dependent transcriptional activity of NOS.*Proc Am Assoc Phys.*;110:22-31.
- **Westphal S., Rading, Luley C. et al. (2003):**Antihypertensive treatment and homocysteine concentration.*Metabolism* ;52(3):261-263.

- **Wilmink H.W., Stroes E.S. and Erkelens T.J.(2000):** Folic acid improves endothelial dysfunction in type 2 diabetes - an effect independent of homocysteine-lowering .*Arterioscler.Thromb Vasc.Biol.*;20:185-188.
- **Wolf N., Quaranta M. and Prescott N.J.(2008):** Psoriasis is associated with pleotropic susceptibility loci identified in type II diabetes and chronic disease.*J Med Genet* .;45:114-116.

(Y)

- **Yap S., Naughten E.R. , Wileken B. et al.(2000):** Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine B-synthetase deficiency, effects of homocysteine lowering therapy. *Seminars in thrombosis and homeostasis*;26(3):335-40.

(Z)

- **Zacho J., Tybjaerg- Hansen A . , Jensen J.S. et al. (2008):** Genetically elevated C reactive protein and ischemic vascular disease. *N Engl J Med.*;359:1897-1908.
- **Zenz R. (2005):** Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. *Nature J. of medicine* ;437 (7057): 369–75.